Many MindedCardiovascular Trial Shows Vascular Benefits from Longevity Supplement
Professor Christian Heiss led a randomized, double-blind trial testing NOVOS Core (a supplement containing 14 ingredients) in 61 generally healthy adults aged 53–60. Of these, 43 completed primary analysis (24 supplement, 19 placebo) after significant attrition. At six months, participants taking NOVOS Core showed statistically significant improvements versus placebo: flow-mediated dilation increased by 2.6 percentage points (5.5% to 8.1%), pulse wave velocity decreased by 0.78 m/s, and systolic blood pressure dropped 8.5 mmHg. The supplement showed no meaningful changes in cholesterol markers. Blood pressure measurements were taken only twice (baseline and six months), potentially influenced by sleep quality. The study was recently published in the European Heart Journal Open.
These vascular improvements suggest NOVOS Core could reduce cardiovascular disease risk through accessible supplementation. For populations where blood pressure management is costly or inaccessible, this trial provides evidence that a single supplement might lower key risk markers without pharmaceutical intervention. However, the control group was older at enrollment (mean age 53) than the supplement group (mean age 60), and high attrition with unexplained causes may have altered results. The effects were measured at six months, with acute improvements at one hour post-dose not showing statistical significance at follow-up. This trial moves abundance potential for cardiovascular health by demonstrating a low-cost intervention that addresses measurable vascular function—though its real-world impact depends on consistent accessibility and addressing the study’s limitations in participant selection and retention.
Source: Lifespan.io